Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform PRINCETON, N.J.—June 24, 2020. Certara®, the global leader in biosimulation, today announced the launch of version 8.3 of its Phoenix™ platform, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. Version 8.3 delivers new features to drive efficiencies and … Continued
Category: Press Release
PRINCETON, N.J.—May 21, 2020 — New executives bring strategic and cross-disciplinary expertise to navigate changing regulatory environments
Certara applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19
Version 19 offers mechanistic models for assessing maternal-fetal drug risk, developing drug formulations, and optimizing dermal and transdermal drug development
Funded by the Bill & Melinda Gates Foundation, the online Center helps accelerate therapeutics for COVID-19 by integrating clinical pharmacology, innovation and collaboration
PRINCETON, NJ – Feb. 25, 2020 – Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc. Acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease.
PRINCETON, NJ – Feb. 10, 2020 – Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
PRINCETON, NJ – Jan. 23, 2020 – Certara today reported that more than 90% of novel new drug approvals by the US Food and Drug Administration (FDA) in 2019 were supported by Certara software or services.
PRINCETON, NJ – Jan. 8, 2020 – Certara’s Simcyp® Simulator’s MechDermA™ model provided safety label claim and pediatric dosing information without the need for testing in clinical patients for a topical drug product.
PRINCETON, NJ – Dec. 10, 2019 – LEO Pharma has licensed Certara’s proprietary Simcyp®️ Population-based Simulator and joined its Consortium.